Preferred Label : lercanidipine hydrochloride;
UMLS semantic type : T109 - Organic Chemical;
CAS number : 132866-11-6; OA8TFX68PE;
Is substance : O;
UNII : OA8TFX68PE;
InChIKey : WMFYOYKPJLRMJI-UHFFFAOYSA-N;
Origin ID : M0324284;
UMLS CUI : C0595331;
CISMeF manual mappings
- Exact mapping(s) to DCI
- Related record
- Semantic type(s)
- UMLS correspondences (same concept)
http://www.has-sante.fr/portail/jcms/c_2588565/fr/zanidip
http://www.has-sante.fr/portail/jcms/c_1012035/zanidip
2016
false
France
French
insurance, health, reimbursement
lercanidipine hydrochloride
lercanidipine
administration, oral
lercanidipine
calcium channel blockers
antihypertensive agents
hypertension
dihydropyridines
treatment outcome
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2588562/fr/lercan
http://www.has-sante.fr/portail/jcms/c_1024725/lercan
2016
false
France
French
treatment outcome
lercanidipine hydrochloride
hypertension
lercanidipine
administration, oral
dihydropyridines
antihypertensive agents
insurance, health, reimbursement
calcium channel blockers
lercanidipine
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2044640/fr/zanextra
2015
false
France
French
lercanidipine hydrochloride
hypertension
lercanidipine
administration, oral
insurance, health, reimbursement
treatment outcome
enalapril
drug combinations
angiotensin-converting enzyme inhibitors
antihypertensive agents
calcium channel blockers
dihydropyridines
enalapril and lercanidipine
enalapril maleate
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2043741/fr/lercapress
2015
false
France
French
lercanidipine hydrochloride
lercanidipine
tablets
administration, oral
drug combinations
insurance, health, reimbursement
enalapril
hypertension
antihypertensive agents
calcium channel blockers
dihydropyridines
angiotensin-converting enzyme inhibitors
treatment outcome
enalapril and lercanidipine
dihydropyridines
enalapril maleate
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1710101/fr/lercapress
http://www.has-sante.fr/portail/jcms/c_1710100/fr/lercapress20112013avisct13258
http://www.has-sante.fr/portail/jcms/c_744011/fr/lercapress-20-mg/10-mg-10-mg/10-mg
2013
France
French
lercanidipine hydrochloride
lercanidipine
tablets
administration, oral
enalapril
insurance, health, reimbursement
drug combinations
calcium channel blockers
antihypertensive agents
angiotensin-converting enzyme inhibitors
treatment outcome
dihydropyridines
enalapril and lercanidipine
dihydropyridines
enalapril maleate
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_744024/zanextra-20-mg/10-mg
http://www.has-sante.fr/portail/jcms/c_1710097/fr/zanextra
http://www.has-sante.fr/portail/jcms/c_1710096/fr/zanextra20112013avisct13256
2013
France
French
lercanidipine hydrochloride
lercanidipine
administration, oral
insurance, health, reimbursement
treatment outcome
enalapril
drug combinations
angiotensin-converting enzyme inhibitors
antihypertensive agents
calcium channel blockers
dihydropyridines
enalapril and lercanidipine
enalapril maleate
evaluation of the transparency committee
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63565415
2012
France
summary of product characteristics
package leaflet
lercanidipine hydrochloride
lercanidipine
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67015130
2012
France
summary of product characteristics
package leaflet
lercanidipine hydrochloride
tablets
lercanidipine
---
